Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells

Experimental Eye Research

Volumn 83, Issue 6, 2006, Pages 1335-1339

  Laengle, Ulrich Wilhelm ^a   Markstein, Rudolf ^a   Pralet, Dominique ^a   Seewald, Wolfgang ^a   Roman, Danielle ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

dopamine D1 receptor antagonist; dopamine D2 receptor agonist; GLC756; in vitro model; latanoprost; mast cells; timolol; TNF ; topical glaucoma medication

Indexed keywords

ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLC 756; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLAUCOMA; INCUBATION TIME; INFLAMMATION; LEUKEMIA CELL; MAST CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; MAST CELLS; PROSTAGLANDINS F, SYNTHETIC; QUINOLINES; RATS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TIMOLOL; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750446700     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2006.07.008     Document Type: Article

References (40)

1. Alm A., and Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102 (1995) 1743-1752
2. Altintas O., Yuksel N., Karabas V.L., and Demirci G. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur. J. Ophthalmol. 15 (2005) 158-161
3. Bacon A.S., Ahluwalia P., Irani A.M., Schwartz L.B., Holgate S.T., Church M.K., and McGill J.I. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J. Allergy Clin. Immunol. 106 (2000) 948-954
4. Barsumian E.L., Isersky C., Petrino M.G., and Siraganian R.P. IgE-induced histamine release from rat basophilic leukemia cell lines: isolation of releasing and non-releasing clones. Eur. J. Immunol. 11 (1981) 317-323
5. Bielory L. Allergic and immunologic disorders of the eye. Part I: immunology of the eye. J. Allergy Clin. Immunol. 106 (2000) 805-816
6. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J. Allergy Clin. Immunol. 106 (2000) 1019-1032
7. Brazis P., de Mora F., Ferrer L., and Puigdemont A. IgE enhances Fc epsilon RI expression and IgE-dependent TNF-alpha release from canine skin mast cells. Vet. Immunol. Immunopathol. 85 (2002) 205-212
8. Chiou G.C., and Chen Y.J. Effects of dopamine agonist, bromocriptine, and some dopamine antagonists on ocular blood flow. J. Ocul. Pharmacol. 8 (1992) 285-294
9. Cho S.H., Woo C.H., Yoon S.B., and Kim J.H. Protein kinase Cdelta functions downstream of Ca2+ mobilization in FcepsilonRI signaling to degranulation in mast cells. J. Allergy Clin. Immunol. 114 (2004) 1085-1092
10. Church M.K., and McGill J.I. Human ocular mast cells. Curr. Opin. Allergy Clin. Immunol. 2 (2002) 419-422
11. Cook E.B., Stahl J.L., Barney N.P., and Graziano F.M. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann. Allergy Asthma Immunol. 84 (2000) 504-508
12. Costagliola C., Prete A.D., Incorvaia C., Fusco R., Parmeggiani F., and Di Giovanni A. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch. Clin. Exp. Ophthalmol. 239 (2001) 809-814
13. Eisenberg D.L., and Camras C.B. A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. Drug Saf. 20 (1999) 505-514
14. Fong Y., and Lowry S.F. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin. Immunol. Immuopathol. 55 (1990) 157-170
15. Guenoun J.M., Baudouin C., Rat P., Pauly A., Warnet J.M., and Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 46 (2005) 2444-2450
16. Jerstad K.M., and Warshaw E. Allergic contact dermatitis to latanoprost. Am. J. Contact Dermat. 13 (2002) 39-41
17. Konstas A.G., Kozobolis V.P., Tersis I., Leech J., and Stewart W.C. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye 17 (2003) 41-46
18. Krauss A.H., and Woodward D.F. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv. Ophthalmol. 49 Suppl. 1 (2004) 5-11
19. 1 antagonist, and timolol on endotoxin-induced TNF-alpha release in serum of rats. Eur. J. Ophthalmol. 3 (2006) 401-406
20. Lantz C.S., Yamaguchi M., Oettgen H.C., Katona I.M., Miyajima I., Kinet J.P., and Galli S.J. IgE regulates mouse basophil Fc epsilon RI expression in vivo. J. Immunol. 158 (1997) 2517-2521
21. MacGlashan Jr. D. IgE and Fc{epsilon}RI regulation. Ann. N.Y. Acad. Sci. 1050 (2005) 73-88
22. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., and Lichtenstein L.M. Serum IgE level drives basophil and mast cell IgE receptor display. Int. Arch. Allergy Immunol. 113 (1997) 45-47
23. Markstein R., Gull P., Rudeberg C., Urwyler S., Jaton A.L., Kalkman H.O., Dixon A.K., and Hoyer D. SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J. Neural. Transm. 103 (1996) 17-30
24. Noecker R.J., Herrygers L.A., and Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23 (2004) 490-496
25. Ohno I., Tanno Y., Yamauchi K., and Takishima T. Gene expression and production of tumour necrosis factor by a rat basophilic leukaemia cell line (RBL-2H3) with IgE receptor triggering. Immunology 70 (1990) 88-93
26. Pruente C., and Flammer J. The novel dopamine D1 antagonist and D2 agonist, SDZ GLC 756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma. Ophthalmology 102 (1995) 1291-1297
27. Prünte C., Flammer J., Markstein R., and Rudin M. Quantification of optic nerve blood flow using MR-imaging. Invest. Ophthalmol. Vis. Sci. 36 (1995) 247-251
28. Prunte C., Nuttli I., and Markstein R. Topical SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, lowers intraocular pressure in conscious rabbits. Jpn. J. Ophthalmol. 40 (1996) 167-173
29. Sacca S., Pascotto A., Siniscalchi C., and Rolando M. Ocular complications of latanoprost in uveitic glaucoma: three case reports. J. Ocul. Pharmacol. Ther. 17 (2001) 107-113
30. Seldin D.C., Adelman S., Austen K.F., Stevens R.L., Hein A., Caufield J.P., and Woodbury R.G. Homology of the rat basolüphilic leukaemia cell and the rat mucosal mast cell. Proc. Natl. Acad. Sci. USA 82 (1985) 3871-3875
31. Shaikh N., Rivera J., Hewlett B.R., Stead R.H., Zhu F.G., and Marshall J.S. Mast cell Fc epsilonRI expression in the rat intestinal mucosa and tongue is enhanced during Nippostrongylus brasiliensis infection and can be up-regulated by in vivo administration of IgE. J. Immunol. 158 (1997) 3805-3812
32. Sharif N.A., Kelly C.R., Crider J.Y., Williams G.W., and Xu S.X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19 (2003) 501-515
33. Smith S.J., Piliponsky A.M., Rosenhead F., Elchalal U., Nagler A., and Levi-Schaffer F. Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clin. Exp. Allergy 32 (2002) 906-913
34. Solomon A., Pe'er J., and Levi-Schaffer. Advances in ocular allergy: basic mechanisms, clinical patterns and new therapies. Curr. Opin. Allergy Clin. Immun. 1 (2001) 477-482
35. Stahl J.L., Cook E.B., Barney N.P., and Graziano F.M. Pathophysiology of ocular allergy: the roles of conjunctival mast cells and epithelial cells. Curr. Allergy Asthma Rep. 2 (2002) 332-339
36. Welker P., Grabbe J., Zuberbier T., and Henz B.M. GM-CSF downregulates expression of tryptase, Fc epsilon RI and histamine in HMC-1 mast cells. Int. Arch. Allergy Immunol. 113 (1997) 284-286
37. Xu B., Makris A., Thornton C., and Hennessy A. Glucocorticoids inhibit placental cytokines from cultured normal and preeclamptic placental explants. Placenta 26 (2005) 654-660
38. Yamaguchi M., Lantz C.S., Oettgen H.C., Katona I.M., Fleming T., Miyajima I., Kinet J.P., and Galli S.J. IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J. Exp. Med. 185 (1997) 663-672
39. Yamaguchi M., Sayama K., Yano K., Lantz C.S., Noben-Trauth N., Ra C., Costa J.J., and Galli S.J. IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J. Immunol. 162 (1999) 5455-5465
40. Ziai N., Dolan J.W., Kacere R.D., and Brubaker R.F. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111 (1993) 1351-1358